CSOP Bitcoin Futures ETF
03066
ChinaAMC Bitcoin ETF
03042
Bosera HashKey Bitcoin ETF
03008
Harvest Bitcoin Spot ETF
03439
Samsung Bitcoin Futures Active ETF
03135
HK Stock MarketDetailed Quotes
03759 PHARMARON
- 13.720
- -0.300-2.14%
Market Closed Dec 27 16:08 CST
24.31BMarket Cap11.64P/E (TTM)
13.980High13.340Low10.50MVolume13.980Open14.020Pre Close142.39MTurnover3.55%Turnover Ratio13.76P/E (Static)1.77BShares24.85052wk High1.64P/B4.05BFloat Cap7.98052wk Low0.22Dividend TTM295.34MShs Float93.548Historical High0.222Dividend LFY4.57%Amplitude7.980Historical Low13.564Avg Price100Lot Size1.62%Div YieldTTM1.62%Div Yield LFY
PHARMARON Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 3.00%8.82B | -0.63%5.6B | -1.95%2.67B | 12.39%11.54B | 15.64%8.56B | 21.70%5.64B | 29.53%2.72B | 37.92%10.27B | 39.63%7.4B | 41.06%4.63B |
| Operating income | 3.00%8.82B | -0.63%5.6B | -1.95%2.67B | 12.39%11.54B | 15.64%8.56B | 21.70%5.64B | 29.53%2.72B | 37.92%10.27B | 39.63%7.4B | 41.06%4.63B |
| Cost of sales | ---- | -4.27%-3.76B | ---- | -14.21%-7.44B | ---- | -19.24%-3.6B | ---- | -36.58%-6.52B | ---- | -44.17%-3.02B |
| Operating expenses | -6.36%-5.83B | -4.27%-3.76B | -2.84%-1.8B | -14.21%-7.44B | -16.60%-5.48B | -19.24%-3.6B | -24.28%-1.75B | -36.58%-6.52B | -39.81%-4.7B | -44.17%-3.02B |
| Gross profit | -2.97%2.99B | -9.30%1.85B | -10.55%872.15M | 9.22%4.09B | 13.95%3.08B | 26.31%2.04B | 40.16%974.97M | 40.31%3.75B | 39.34%2.7B | 35.59%1.61B |
| Selling expenses | 3.80%-186.56M | 3.02%-122.95M | 0.41%-55.47M | -9.87%-252.78M | -18.94%-193.92M | -17.27%-126.78M | -18.95%-55.7M | -47.84%-230.07M | -56.20%-163.04M | -69.63%-108.11M |
| Administrative expenses | 0.62%-1.21B | 0.50%-841.22M | 3.81%-398.61M | -7.75%-1.67B | -17.15%-1.21B | -27.89%-845.44M | -42.63%-414.38M | -70.85%-1.55B | -73.19%-1.04B | -72.34%-661.07M |
| Research and development expenses | -11.96%-332.25M | -14.06%-207.8M | -21.82%-93.61M | -58.78%-448.28M | -67.22%-296.76M | -117.74%-182.18M | -93.81%-76.84M | -86.02%-282.33M | -61.55%-177.47M | -29.79%-83.67M |
| Profit from asset sales | -9,732.09%-23.92M | ---- | -17,640.70%-20M | ---- | 118.51%248.31K | ---- | 124.01%114K | ---- | -17.65%-1.34M | ---- |
| Revaluation surplus | -155.03%-22.12M | ---- | -103.94%-1.13M | ---- | -48.12%40.2M | ---- | -36.42%28.58M | ---- | 328.45%77.49M | ---- |
| -Changes in the fair value of other assets | -155.03%-22.12M | ---- | -103.94%-1.13M | ---- | -48.12%40.2M | ---- | -36.42%28.58M | ---- | 328.45%77.49M | ---- |
| Impairment and provision | -25.70%-29.68M | -114.13%-22.94M | -48.33%-6.47M | -69.33%-35.83M | -95.17%-23.61M | -69.00%-10.71M | -1,025.65%-4.36M | -106.03%-21.16M | -82.15%-12.1M | -1,443.01%-6.34M |
| -Other impairment is provision | -25.70%-29.68M | -114.13%-22.94M | -48.33%-6.47M | -69.33%-35.83M | -95.17%-23.61M | -69.00%-10.71M | -1,025.65%-4.36M | -106.03%-21.16M | -82.15%-12.1M | -1,443.01%-6.34M |
| Operating interest expense | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -414.60%-81.24M |
| Special items of operating profit | 521.30%659.56M | 549.74%742.27M | 81.86%64.63M | 65.17%336.11M | 132.75%106.16M | 53.44%114.24M | 210.94%35.54M | -57.25%203.49M | -72.56%45.61M | 623.82%74.45M |
| Operating profit | 22.45%1.76B | 41.44%1.4B | -29.53%331.85M | 8.28%2.02B | 3.79%1.44B | 32.05%986.57M | 30.70%470.91M | 1.54%1.87B | 13.73%1.38B | 11.03%747.14M |
| Financing cost | -21.96%-132.74M | -55.29%-138.25M | -61.25%-63.44M | -8.89%-182.19M | 32.76%-108.84M | ---89.03M | 2.22%-39.34M | ---167.31M | -1,282.67%-161.87M | ---- |
| Share of profits of associates | ---- | -375.96%-30.31M | ---- | 93.84%-2.08M | ---- | 347.40%10.98M | ---- | -147.12%-33.85M | ---- | 36.52%-4.44M |
| Special items of earning before tax | 28.90%-5.36M | ---- | 104.11%204.32K | ---- | 51.46%-7.54M | ---- | -27.90%-4.97M | ---- | -349.98%-15.53M | ---- |
| Earning before tax | 22.78%1.62B | 35.04%1.23B | -37.03%268.62M | 10.29%1.84B | 9.40%1.32B | 22.33%908.53M | 34.92%426.6M | -12.80%1.67B | 0.41%1.21B | 11.53%742.7M |
| Tax | -35.54%-252.67M | -15.63%-143.91M | 31.07%-52.7M | 18.50%-256.11M | 29.20%-186.42M | 29.84%-124.46M | 3.50%-76.45M | -8.02%-314.25M | -32.55%-263.29M | -49.56%-177.4M |
| After-tax profit from continuing operations | 20.69%1.37B | 38.12%1.08B | -38.33%215.92M | 16.98%1.58B | 20.16%1.13B | 38.70%784.07M | 47.77%350.15M | -16.54%1.35B | -5.95%944.18M | 3.29%565.3M |
| Earning after tax | 20.69%1.37B | 38.12%1.08B | -38.33%215.92M | 16.98%1.58B | 20.16%1.13B | 38.70%784.07M | 47.77%350.15M | -16.54%1.35B | -5.95%944.18M | 3.29%565.3M |
| Minority profit | -1,064.87%-52.59M | -1,404.05%-30.46M | -873.86%-14.64M | 14.03%-19.32M | 73.33%-4.51M | 89.94%-2.03M | 115.59%1.89M | 45.14%-22.47M | 53.15%-16.93M | -14.80%-20.13M |
| Profit attributable to shareholders | 24.82%1.42B | 41.64%1.11B | -33.80%230.56M | 16.48%1.6B | 18.51%1.14B | 34.28%786.09M | 39.81%348.26M | -17.24%1.37B | -7.59%961.11M | 3.65%585.43M |
| Basic earnings per share | 24.85%0.8028 | 41.42%0.6282 | -33.94%0.13 | 16.55%0.9033 | 18.81%0.643 | -10.10%0.4442 | -6.42%0.1968 | -44.60%0.775 | -38.18%0.5412 | 4.00%0.4941 |
| Diluted earnings per share | 24.89%0.8019 | 41.37%0.6271 | -34.01%0.1298 | 16.54%0.9019 | 18.75%0.6421 | -10.18%0.4436 | -6.29%0.1967 | -43.47%0.7739 | -38.11%0.5407 | 4.04%0.4939 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | Ernst & Young | -- | -- | -- | Ernst & Young | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Trending HK Stocks
HK Crypto ETF HK Crypto ETF
An exchange-traded fund designed to track the price performance of Bitcoin or other major crypto, allowing investors to participate in the market without directly purchasing the assets.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK Crypto ETF, ranked from highest to lowest based on real-time market data. An exchange-traded fund designed to track the price performance of Bitcoin or other major crypto, allowing investors to participate in the market without directly purchasing the assets.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK Crypto ETF, ranked from highest to lowest based on real-time market data.
